CRISPR Therapeutics AG

The gene therapy market is projected to reach $36.55 billion by 2032, with the FDA approving three transformative cell therapies in December. Five biotech companies are advancing therapies across diabetes, sickle cell disease, cardiovascular disease, liver disease, and chronic granulomatous disease, with recent clinical data demonstrating signifi...

The article recommends three growth stocks for long-term investors: Amazon, leveraging AWS profitability and expanding AI/advertising segments; Vertex Pharmaceuticals, with a strong cystic fibrosis franchise and promising late-stage drug candidates; and TJX Companies, thriving with its off-price retail model and expansion plans. All three are pos...

The global gene therapy market is projected to grow from $9.50 billion in 2024 to $58.87 billion by 2034, with a 20% CAGR. North America dominates the market, and key growth drivers include advanced research, viral vector technologies, and expanding applications across various diseases.

CRISPR Therapeutics (CRSP) stock is trading near 5-year lows, but the company's gene editing treatment CASGEVY for sickle cell disease and beta-thalassemia has been approved in multiple jurisdictions. The company's future growth potential in gene editing is promising, but the high cost of CASGEVY may be a challenge.

Vertex Pharmaceuticals reported a wider-than-expected Q2 loss due to costs related to the acquisition of Alpine Immune Sciences. However, the company's strong fundamentals, including its dominant position in the cystic fibrosis market and a robust pipeline, make it a good long-term investment despite the recent stock price dip.